NCT00657254View on ClinicalTrials.gov

Extension Program for Bay 43-9006

PHASE2CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions

NeoplasmMetastasis

Interventions

DRUG

Nexavar (Sorafenib, BAY43-9006)

Bay 43-9006 400mg (2 x 200mg tablets) orally twice daily until withdrawal.

Trial Locations (6)

1000

Bruxelles - Brussel

44625

Herne

45147

Essen

02115-6084

Boston

L8V 5C2

Hamilton

M5G 2M9

Toronto

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY